表紙:抗けいれん薬の世界市場(2021年~2028年)
市場調査レポート
商品コード
977292

抗けいれん薬の世界市場(2021年~2028年)

Global Anticonvulsants Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
抗けいれん薬の世界市場(2021年~2028年)
出版日: 2021年07月07日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の抗けいれん薬市場の成長は、米国食品医薬品局(FDA)からの抗けいれん薬の承認の増加によって推進されており、同市場の増加に大きく貢献しています。また、てんかん疾患の有病率の上昇は、予測期間の市場成長を促進すると予測されています。

抗けいれん薬は、主にてんかんの治療のために開発されています。2018年、FDAは、マリファナ由来の有効成分を含む最初の薬剤を承認し、レノックス・ガストー症候群やドラベ症候群などのまれで重度のてんかんを治療しており、これらの抗けいれん薬の導入が、予測期間の市場成長を推進すると予測されています。

ただし、抗けいれん薬による口内のただれ、水ぶくれ、潰瘍などの副作用や体内の白血球と血小板の数の深刻な減少、再生不良性貧血、肝不全など、致命的となる可能性のある特異体質副作用などは同市場の成長を妨げる可能性があるとされています。

当レポートは、世界の抗けいれん薬市場について調査しており、市場の機会や影響、成長および抑制要因、医薬品クラス・用途・投与経路・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 医薬品クラス別
  • 用途別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第4章 市場力学

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 COVID-19分析

  • 市場でのCovid-19の分析
  • Covid-19における価格力学
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 市場分析:医薬品クラス別

  • イントロダクション
  • 市場規模分析および前年比成長分析
  • 市場魅力指数
    • バルビツール酸塩
    • ベンゾジアゼピン
    • ヒダントイン
    • スクシンイミド
    • カルボキサミド
    • 臭化物
    • カルバマート
    • スルホンアミド
    • フルクトース誘導体
    • ピロリジン
    • トリアジン
    • 脂肪酸
    • その他

第8章 市場分析:用途別

  • イントロダクション
  • 市場規模分析および前年比成長分析
  • 市場魅力指数
    • てんかん
    • 片頭痛
    • 線維筋痛症
    • 神経因性疼痛
    • 不安
    • 双極性障害

第9章 市場分析:投与経路別

  • イントロダクション
  • 市場規模分析および前年比成長分析
  • 市場魅力指数
    • 経腸
    • 非経口
    • 局所

第10章 市場分析:流通チャネル別

  • イントロダクション
  • 市場規模分析および前年比成長分析
  • 市場魅力指数
    • 病院薬局
    • 薬局
    • その他

第11章 市場分析:地域別

  • イントロダクション
  • 市場規模分析および前年比成長分析
  • 市場魅力指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市場の位置づけ/シェア分析
  • 合併と買収の分析

第13章 企業プロファイル

  • Abbott Laboratories.
    • 企業概要
    • 製品ポートフォリオ・概要
    • 要点
    • 財務概要
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Sanofi S.A.
  • UCB Group
  • Shire Plc.
  • GlaxoSmithKline Plc.

第14章 重要考察

第15章 DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH2895

Market Overview

The global Anticonvulsants market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

The anticonvulsants are the diverse group of the pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder. They seem to act as mood stabilizers, and for the treatment of neuropathic pain.

Market Dynamics

The global anticonvulsants drug market growth is driven by the Increasing approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA). It is highly contributing to the increase in the anticonvulsants market.

The rising prevalence of epilepsy disease is expected to drive the market growth in the forecast period

The anticonvulsants market size is expected to increase over the forecast period, owing to the rising prevalence of epilepsy globally. According to the World Health Organization (WHO) January 2019 report, around 50 million people are affected by epilepsy worldwide. Moreover, it is estimated that around 2.4 million new cases of epilepsy are diagnosed every year globally. Increasing approval of anticonvulsant drugs from the U.S. Food and Drug Administration (FDA) is highly contributing to the increase in the anticonvulsants market revenue. According to Epilepsy Society of U.K. 2019 data, over 20 drugs are available to treat epilepsy, such as barbiturates, carboxamides, carbamates, and GABA analogs. Around 25 generics are present in the market. Thus the rising prevalence of epilepsy disease ids driving the market growth in the forecast period.

Introduction of anticonvulsant drugs projected to drive the market growth

Anticonvulsant drugs are primarily developed to treat epilepsy, a neurological condition that affects around 50 million people worldwide. They reduce seizure frequency by suppressing neuronal excitability via various molecular targets in the synapse, including voltage-gated ion channels, voltage-gated GABAA (γ-aminobutyric acid type A) glutamate receptors. There are around 24 anticonvulsants drugs approved by the FDA.

In 2018, FDA approved the first drug containing an active ingredient derived from marijuana to treat rare, severe forms of epilepsy such as Lennox-Gastaut syndrome and Dravet syndrome. These factors are driving the market growth in the forecast period.

Side effects such as sores, blisters, or ulcers in the mouth are likely to hinder the market growth

However, the side effects such as sores, blisters or ulcers in the mouth, excessive bleeding in wounds, stomach pain and tenderness, fever, and unusual infections are major restraining factors for anticonvulsants market growth. According to the Epilepsy Foundation report of 2013, there are some unpredictable side effects known as idiosyncratic side effects that can be fatal, including a serious drop in the number of white blood cells and platelets in the body, Aplastic anemia, and liver failure.

COVID-19 Impact Analysis

The COVID-19 pandemic has impacted care delivery to people with epilepsy (PWE) in multiple ways, including limitations on in-person contact and restrictions on neurophysiological procedures. To better study the pandemic's effect on PWE, members of the American Epilepsy Society were surveyed between April 30 and June 14, 2020. There were 366 initial responses (9% response rate), and 337 respondents remained for analysis after screening out non-completers and those not directly involved with clinical care; the majority were physicians from the United States. About a third (30%) of respondents stated that they had patients with COVID-19 and reported no significant change in seizure frequency. Conversely, one-third of respondents reported new-onset seizures in patients with COVID-19 who had no prior history of seizures. The majority of respondents felt that there were at least some barriers for PWE in receiving appropriate clinical care, neurophysiologic procedures, and elective surgery.

Medication shortages were noted by approximately 30% of respondents, with no clear pattern in types of medication involved. Telehealth was overwhelmingly found to have value. Among the survey's limitations was that it was administered at a single point in time in a rapidly changing pandemic. The survey showed that almost all respondents were affected by the pandemic in a variety of ways. Thus the rising prevalence of pandemics on the person affected with epilepsy is driving the anticonvulsants market.

Segment Analysis

Barbiturates, segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Barbiturates act as central nervous system depressants. Barbiturates are derivatives of a chemical called barbituric acid. Various barbiturate drugs are available in the market; however, all have a sedative effect on the central nervous system and are clinically prescribed for anxiety. Barbiturates are also used in the treatment of epilepsy, insomnia, and status epilepticus. Barbiturate drugs are available in pill form and can be taken orally and intravenously. Barbiturates are subjected to the Drug Abuse Prevention, and Control Act in the U.S. Hence, the manufacture and distribution of these drugs are strictly controlled. Barbiturate drugs enhance one of the brain's primary neurotransmitters, known as gamma-aminobutyric acid (GABA). An increase in GABA has a sedative effect on the user's brain. The effect of barbiturate lasts between 4 hours and 16 hours, depending on the dose's type and strength. The rising prevalence of seizures across the world is driving the growth of the segment.

For instance, according to the World Health Organization (WHO), up to 10% of the world population has one seizure during a lifetime. The WHO also states that there are about 50 million people worldwide presently living with epilepsy. Every year, 30 to 50 per 100000 people are newly diagnosed with epilepsy in high-income countries, and this count is approximately two times higher among low and middle-income countries. These factors are driving the market growth in the forecast period.

The hospital pharmacy are expected to dominate the the anticonvulsants market during the forecast period

The hospital pharmacies held the largest share in the anticonvulsants market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global anticonvulsants market

North America is expected to hold dominant position in the anticonvulsants market during the forecast period, owing to increasing demand for treatment of epilepsy. For instance, according to the WHO 2019 report, in up to 70% of people living with epilepsy globally, seizure is controlled with appropriate diagnosis and use of anti-epileptic medicines. Low-cost treatment is available, with daily medication that costs US$ 5 per year. Pain management implants and devices such as neuromodulators are gaining market acceptance among medical professionals, while acupuncture and acupressure are world-renowned pain relief techniques along with physiotherapy that people adopt. These factors are driving the market growth in the forecast period.

Competitive Landscape

The anticonvulsants market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Pfizer Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., UCB Group, Shire Plc., GlaxoSmithKline Plc., Cephalon Inc., and Astrazeneca Plc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anticonvulsants market globally.

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the anticonvulsants market segmentation drug class, application, route of administration, distribution channel and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in anticonvulsants market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of anticonvulsants market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global anticonvulsants market report would provide an access to an approx. 74 market data table, 72 figures and 330 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Anticonvulsants Market - By Drug Class

  • Barbiturates

Hyper-CVAD Regimen

CALGB 8811 Regimen

Linker Regimen

Nucleoside Metabolic Inhibitors

  • Benzodiazepines
  • Hydantoins
  • Succinimides
  • Carboxamides
  • Bromide
  • Carbamates
  • Sulfonamide
  • Fructose derivatives
  • Pyrrolidines
  • Triazines
  • Fatty acids
  • Others

Global Anticonvulsants Market - By Application

  • Epilepsy
  • Migraine
  • Fibromyalgia
  • Neuropathic pain
  • Anxiety
  • Bipolar disorder

Global Anticonvulsants Market - By Route of Administration

  • Enteral
  • Parenteral
  • Topical

Global Anticonvulsants Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Others

Global Anticonvulsants Market - By Region

  • North America
  • South America
  • Europe

Table of Contents

1. Global Anticonvulsants Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Anticonvulsants Market - Market Definition and Overview

3. Global Anticonvulsants Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Application
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Anticonvulsants Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness about the anticonvulsants available in the market
      • 4.1.1.2. Rising cases of epileptic seizures
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent Regulatory Pathways
      • 4.1.2.2. High costs and unavailability of convenient dosage
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Anticonvulsants Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Anticonvulsants Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Anticonvulsants Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Barbiturates*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 7.2.3. Hyper-CVAD Regimen
    • 7.2.4. CALGB 8811 Regimen
    • 7.2.5. Linker Regimen
    • 7.2.6. Nucleoside Metabolic Inhibitors
  • 7.3. Benzodiazepines
  • 7.4. Hydantoins
  • 7.5. Succinimides
  • 7.6. Carboxamides
  • 7.7. Bromides
  • 7.8. Carbamates
  • 7.9. Sulfonamides
  • 7.10. Fructose derivatives
  • 7.11. Pyrrolidines
  • 7.12. Triazines
  • 7.13. Fatty acids
  • 7.14. Others

8. Global Anticonvulsants Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Epilepsy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Migraine
  • 8.4. Fibromyalgia
  • 8.5. Neuropathic pain
  • 8.6. Anxiety
  • 8.7. Bipolar disorder

9. Global Anticonvulsants Market - By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Enteral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Parenteral
  • 9.4. Topical

10. Global Anticonvulsants Market - By Distribution channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment
    • 10.1.2. Market Attractiveness Index, By Distribution channel Segment
  • 10.2. Hospital Pharmacy*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Pharmacy stores
  • 10.4. Others

11. Global Anticonvulsants Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel

12. Global Anticonvulsants Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of key companies to watch
  • 12.5. List of the company with disruptive technology
  • 12.6. List of start-up companies

13. Global Anticonvulsants Market- Company Profiles

  • 13.1. Abbott Laboratories.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Teva Pharmaceutical Industries Ltd.
  • 13.3. Johnson & Johnson
  • 13.4. Novartis AG
  • 13.5. Pfizer Inc.
  • 13.6. Valeant Pharmaceuticals International, Inc.
  • 13.7. Sanofi S.A.
  • 13.8. UCB Group
  • 13.9. Shire Plc.
  • 13.10. GlaxoSmithKline Plc.

LIST NOT EXHAUSTIVE

14. Global Anticonvulsants Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us